Kite Pharma, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products, services, research and therapies.
The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.
“Anti-CD19 CAR T cell therapy has been explored in both in vitro and animal studies, with positive results.” (Page 14) Read the following document
Kite Pharma, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products designed to target and kill cancer cells. It uses engineered autologous cell therapy, which involves the genetic engineering of T cells. Its lead product candidate, KTE-C19, a CAR-based therapy, which seeks treat patients with refractory diffuse large B-cell lymphoma, primary mediastinal large B-Cell lymphoma, and transformed follicular lymphoma. The company was founded by Arie S. Belldegrun, James S. Economou and Joshua A. Kazam in June 2009 and is headquartered in Santa Monica, CA. [Source: MarketWatch]
Company Website: http://kitepharma.com